Antiplatelet Agents in Cardiovascular Disease

Platelet Activation and Aggregation Cascade

• Platelets respond to vascular injury through multiple parallel activation pathways: (1) collagen exposure triggering glycoprotein VI signaling; (2) tissue factor/thrombin generation activating protease-activated receptors (PAR-1, PAR-4); (3) adenosine diphosphate (ADP) release from platelet dense granules activating P2Y1 and P2Y12 receptors; and (4) thromboxane A2 (TXA2) synthesis via COX-1 enzyme, which activates the thromboxane-prostanoid (TP) receptor
• These converging signals induce platelet shape change, cytoplasmic calcium mobilization, and exposure of phosphatidylserine on the platelet membrane, creating a prothrombotic surface
• Final common pathway involves glycoprotein IIb/IIIa integrin activation, enabling fibrinogen cross-linking and platelet aggregate formation

Aspirin (COX Inhibitor) Mechanism

• Irreversibly acetylates serine 529 in the active site of cyclooxygenase-1 (COX-1) on platelet membranes, permanently blocking conversion of arachidonic acid to prostaglandin H2 (PGH2)
• This prevents synthesis of thromboxane A2 (TXA2), a potent platelet agonist and vasoconstrictor that normally amplifies ADP and collagen-induced activation
• The irreversible inhibition means antiplatelet effect persists for the 7-10 day lifespan of circulating platelets (anucleate cells cannot synthesize new COX-1)
• Aspirin has the highest antiplatelet potency at low doses (75-325 mg daily); higher doses provide no additional benefit and increase risk of gastrointestinal (GI) bleeding

P2Y12 Receptor Antagonists (Thienopyridines and Non-Thienopyridines)

• Clopidogrel (Plavix) and prasugrel (Effient) are thienopyridines that require hepatic metabolic activation via the cytochrome P450 system (CYP3A4, CYP2C19, CYP2B6) to generate active metabolites
• Ticagrelor (Brilinta) is a cyclopentyl-triazolo-pyrimidine with direct reversible binding to P2Y12 and does not require hepatic activation—achieving faster and more potent platelet inhibition
• All P2Y12 inhibitors block ADP-induced platelet aggregation by competitively antagonizing the P2Y12 adenosine diphosphate receptor, preventing coupling to Gi proteins and reducing cAMP-mediated platelet suppression
• The loading dose (300-600 mg clopidogrel, 60 mg prasugrel, 180 mg ticagrelor) achieves 50-60% platelet inhibition within 2-4 hours; maintenance dosing (75 mg clopidogrel daily, 5-10 mg prasugrel daily, 60 mg ticagrelor twice daily) maintains steady-state inhibition at 30-50%

Phosphodiesterase-3 Inhibitor (Cilostazol)

• Increases intracellular cAMP levels in platelets and vascular smooth muscle cells through inhibition of phosphodiesterase-3 (PDE-3), which normally degrades cAMP
• Elevated cAMP directly suppresses platelet activation through multiple mechanisms: (1) prevents calcium mobilization; (2) reduces P-selectin expression; (3) inhibits integrin αIIbβ3 activation
• Also produces vasodilatory effects on peripheral arteries, improving blood flow in patients with claudication

Synergistic Effects of Dual Antiplatelet Therapy (DAPT)

• Aspirin blocks TXA2-mediated activation, while P2Y12 inhibitors block ADP-mediated activation, targeting non-redundant pathways
• This combination achieves additive platelet inhibition (approximately 80-90% reduction in platelet aggregation) superior to monotherapy
• Particularly effective in suppressing stent thrombosis, where multiple activation signals converge on the exposed thrombogenic stent surface

Primary Indications for Antiplatelet Therapy (Secondary Prevention)

• Acute coronary syndromes (ACS): Includes ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and unstable angina—antiplatelet agents are foundational to acute therapy and post-revascularization management
• Stable coronary artery disease (CAD): Chronic aspirin monotherapy reduces recurrent events in patients with prior myocardial infarction (MI), stable angina, or prior coronary revascularization
• Post-percutaneous coronary intervention (PCI): DAPT (aspirin + P2Y12 inhibitor) for 12 months (or shorter in high-bleeding-risk patients) prevents stent thrombosis and recurrent ischemic events
• Ischemic stroke or transient ischemic attack (TIA): Aspirin monotherapy or aspirin-extended-release dipyridamole for secondary stroke prevention in patients with non-cardioembolic ischemic stroke
• Peripheral arterial disease (PAD): Aspirin reduces cardiovascular events and death in patients with symptomatic claudication or critical limb ischemia

Primary Prevention Indications (Selective Use)

• Asymptomatic individuals at very high ASCVD risk: Data support selective aspirin use in adults aged 40-59 years with ≥10% 10-year ASCVD risk and no prior history of bleeding (Class IIb recommendation)
• Chronic stable CAD risk factors: Recent guidelines recommend against routine aspirin for primary prevention in most asymptomatic individuals due to increased bleeding risk outweighing ischemic benefits

Factors Influencing Choice of P2Y12 Inhibitor

• Acute coronary syndrome (ACS) patients benefit from prasugrel or ticagrelor over clopidogrel due to superior clinical outcomes (TRITON-TIMI 38, PLATO trials); prasugrel preferred in STEMI with angiographically confirmed thrombotic lesion
• Clopidogrel remains standard in patients with contraindications to prasugrel (age >75 years, weight <60 kg, prior stroke/TIA) or ticagrelor (bradycardia <60 bpm, AV block, contraindicated beta-blockers)
• Loss-of-function CYP2C19 polymorphisms (especially *2 and *3 alleles) significantly impair clopidogrel activation—patients with these variants show high on-treatment platelet reactivity (HTPR) and increased thrombotic risk; ticagrelor or prasugrel are preferred alternatives
• Prior stroke/TIA: Prasugrel is contraindicated; ticagrelor or clopidogrel preferred (ticagrelor slightly favored in NSTEMI/unstable angina)

Indications for Antiplatelet Therapy—Clinical Scenarios

• Acute Coronary Syndrome (STEMI/NSTEMI/Unstable Angina): Presenting with chest pain, dyspnea, diaphoresis, nausea; elevated cardiac biomarkers (troponin, CK-MB); dual antiplatelet therapy initiated immediately upon presentation (aspirin 325-600 mg, P2Y12 inhibitor loading dose)
• Stable Coronary Artery Disease: Chronic angina with exertion or stress; asymptomatic ischemia detected on stress testing; long-term aspirin monotherapy (81-325 mg daily) as foundational therapy
• Post-PCI with Stent Placement: Coronary angiography revealing obstructive CAD amenable to percutaneous revascularization; DAPT (aspirin + P2Y12 inhibitor) for minimum 12 months (or shorter if high bleeding risk)
• Ischemic Stroke/TIA: Acute focal neurologic deficits (weakness, speech difficulty, visual loss) from non-cardioembolic ischemia; aspirin or aspirin-extended-release dipyridamole initiated for secondary prevention
• Peripheral Arterial Disease: Claudication (leg pain with exertion relieved at rest), critical limb ischemia, or prior peripheral revascularization; aspirin reduces cardiovascular events even if not primarily treating PAD

Clinical Bleeding Manifestations (Adverse Effects)

• Minor bleeding: Epistaxis (nosebleeds), easy bruising, gum bleeding, hematuria—present in 5-10% of patients on DAPT
• Major bleeding: Gastrointestinal hemorrhage (most common site, accounting for 50% of major bleeds), intracranial hemorrhage (most serious), hemoptysis, melena, hematochezia—present in 2-4% of DAPT patients annually
• Risk factors for bleeding: Advanced age (≥75 years), high PRECISE-DAPT score, prior GI bleeding, thrombocytopenia, oral anticoagulation with warfarin/DOACs, chronic kidney disease, elevated serum creatinine

Clinical Assessment and Baseline Evaluation

• History and physical examination: Document type of cardiovascular event (ACS, stroke, PAD), timing of symptom onset, prior antiplatelet use, bleeding history (GI bleeding, intracranial hemorrhage, easy bruising), medication allergies, and contraindications
• Electrocardiogram (ECG): Essential in suspected ACS to identify ST-segment elevation (STEMI, requiring emergent PCI), ST-segment depression/T-wave inversion (NSTEMI/unstable angina, requiring urgent catheterization), or normal baseline (TIA/unstable angina)
• Cardiac biomarkers: Serial troponin (high-sensitivity troponin preferred) at baseline, 3 hours, and 6 hours in suspected ACS; elevation confirms myocardial necrosis and guides antiplatelet intensity; negative serial troponins rule out MI if symptoms clearly cardiac

Laboratory Assessment

• Platelet count: Baseline platelet count <150,000/μL contrainddicates P2Y12 inhibitors; assess for thrombocytopenia from medications or underlying hematologic disease
• Hemoglobin/hematocrit: Baseline assessment for anemia; hemoglobin <7-8 g/dL increases procedural bleeding risk
• Renal function (serum creatinine, eGFR): Creatinine clearance <30 mL/min increases bleeding risk and may necessitate dose adjustments; important for risk stratification
• Liver function tests: Assess baseline hepatic synthetic function, especially in patients receiving clopidogrel (requires hepatic activation) or with cirrhosis
• Genetic testing for CYP2C19 polymorphisms: Emerging utility in clopidogrel selection; *2 and *3 loss-of-function alleles predict reduced clopidogrel responsiveness (HTPR), though cost-benefit and clinical implementation remain debated
• Platelet function testing: Aspirin resistance and clopidogrel resistance (HTPR) can be assessed via platelet aggregometry or VerifyNow testing; clinical utility in guiding therapy remains limited but may identify high-risk patients

Cardiac Imaging and Procedural Findings

• Coronary angiography: Gold standard for identifying coronary artery disease, flow-limiting lesions, and thrombotic burden in ACS; determines need for revascularization and stent type
• Stress testing (exercise, nuclear, echo): Identifies inducible ischemia in stable CAD and guides intensity of antiplatelet/antianginal therapy
• Computed tomography angiography (CTA) chest: May assess for alternative diagnoses (pulmonary embolism, aortic dissection) in chest pain presentations without clear ACS features

Diagnostic Criteria and Risk Stratification

• Universal Definition of MI (4th Edition): Requires troponin elevation above 99th percentile AND evidence of myocardial ischemia (clinical symptoms, ECG changes, imaging abnormalities, or autopsy findings of thrombosis)
• GRACE Risk Score (for ACS): Integrates age, Killip class, systolic BP, heart rate, creatinine, biomarkers, and ST deviation to predict in-hospital and 6-month mortality; high GRACE score (>140) supports aggressive DAPT and early invasive strategy
• PRECISE-DAPT Score (for bleeding risk): Incorporates age, bleeding history, insufficient kidney function, elevated creatinine, elevated troponin, moderate-to-severe hepatic disease, and reduced hemoglobin; scores ≥25 identify patients at high bleeding risk requiring shorter DAPT duration (3-6 months vs. 12 months)

Acute Coronary Syndrome Management (STEMI/NSTEMI/Unstable Angina)

• Aspirin: 325-600 mg oral loading dose (if non-enteric-coated) or 250-500 mg IV (acidsalicylate) if available; achieves 50% platelet inhibition within 20 minutes and near-maximal effect at 1-2 hours; continue 81 mg daily indefinitely (some data support 325 mg daily in STEMI)
• P2Y12 Inhibitor Loading Dose (chosen based on presentation and predicted revascularization strategy):
• Prasugrel 60 mg (or 5 mg if age >75 years or weight <60 kg): Superior outcomes in STEMI (TRITON-TIMI 38 trial); reduced stent thrombosis compared to clopidogrel; contraindicated in prior stroke/TIA
• Ticagrelor 180 mg: Preferred in NSTEMI (PLATO trial); faster onset than clopidogrel; reversible binding allows restoration of platelet function more quickly if emergency CABG needed; administer 60 mg maintenance dose twice daily (vs. clopidogrel/prasugrel daily dosing)
• Clopidogrel 600 mg (older agent): Acceptable if prasugrel/ticagrelor contraindicated or unavailable; slower onset (2-4 hours) and less potent; standard in stable CAD without acute presentation
• Timing: Both aspirin and P2Y12 inhibitor should be administered in the emergency department, ideally before coronary angiography (in STEMI, loading dose given before transfer for primary PCI)

• Anticoagulation: Unfractionated heparin (80 U/kg IV bolus, then 18 U/kg/hr infusion adjusted by aPTT) or low-molecular-weight heparin (enoxaparin 0.5 mg/kg IV, then 1 mg/kg SC q12h) during acute phase and through coronary angiography
• **Glycoprotein IIb/IIIa inhib

Bleeding — the class toxicity

• Gastrointestinal hemorrhage: aspirin blocks COX-1–derived mucosal PGE2/PGI2, removing the stimulus for mucus and bicarbonate secretion and mucosal blood flow — this is a systemic, not topical, effect, so enteric coating does not eliminate ulcer risk. The ACCF/ACG/AHA expert consensus on antiplatelet therapy and GI risk supports proton pump inhibitor co-therapy in patients with prior ulcer/GI bleed, DAPT, or concomitant anticoagulation; prefer pantoprazole over omeprazole/esomeprazole, which inhibit CYP2C19 and blunt clopidogrel bioactivation.
• Intracranial hemorrhage: the most feared bleed; a prior hemorrhagic stroke or prior stroke/TIA contraindicates prasugrel (net harm), and prior ICH contraindicates ticagrelor.
• No specific antidote exists. Management is drug discontinuation, transfusion support, and endoscopic/surgical hemostasis. Per the AHA/ASA spontaneous intracerebral hemorrhage guideline, platelet transfusion is not recommended for antiplatelet-associated ICH outside of surgery — trial evidence suggested harm. Desmopressin is sometimes used with weak evidence. A monoclonal ticagrelor-binding fragment remains investigational.

Agent-specific toxicities

• Aspirin: aspirin-exacerbated respiratory disease (asthma, nasal polyps, aspirin sensitivity — Samter triad) from arachidonate shunting toward cysteinyl leukotrienes; Reye syndrome in children with viral illness; salicylate overdose gives tinnitus and a mixed respiratory alkalosis + metabolic acidosis; low doses reduce urate excretion.
• Ticagrelor: dyspnea (adenosine reuptake inhibition), bradyarrhythmias/ventricular pauses, rising uric acid and creatinine; twice-daily dosing worsens adherence; avoid strong CYP3A4 inhibitors/inducers and severe hepatic impairment.
• Thienopyridines: rare thrombotic thrombocytopenic purpura; ticlopidine (historical) caused neutropenia/agranulocytosis and TTP, which is why it was abandoned.
• Cilostazol: contraindicated in heart failure — PDE-3 inhibitors increase mortality in HFrEF (ACC/AHA PAD guideline); causes headache, palpitations, diarrhea.
• Dipyridamole: headache, flushing, and coronary steal — avoid in severe obstructive CAD.
• Glycoprotein IIb/IIIa inhibitors: profound acute thrombocytopenia (immune-mediated with abciximab) — check platelet counts.

Monitoring and periprocedural holds

• Follow hemoglobin/hematocrit and platelet count and screen for occult bleeding; routine platelet-function assays are not recommended.
• Before elective CABG, ACC/AHA/SCAI revascularization guidance is to hold clopidogrel and ticagrelor several days and prasugrel about a week; aspirin is continued.

• Aspirin's signature lab pattern: prolonged bleeding time/platelet function assay with normal PT, INR, aPTT, and platelet count. A stem describing mucocutaneous bleeding with normal coagulation studies and normal platelets is pointing at a platelet function defect, not a factor deficiency. Because inhibition is irreversible and platelets are anucleate, the effect persists 7–10 days.
• Prasugrel + prior stroke or TIA = contraindicated. This is the single most tested antiplatelet contraindication; the correct next step is ticagrelor or clopidogrel. Also dose-reduce or avoid prasugrel if age >75 years or weight <60 kg.
• New dyspnea on ticagrelor is the drug, not decompensated heart failure. Adenosine reuptake inhibition explains it; the answer is reassurance/continuation, not diuresis or discontinuation. Watch for the associated bradycardia/AV pause.
• Recurrent stent thrombosis on clopidogrel → CYP2C19 loss-of-function allele. Per CPIC guidance, switch to ticagrelor or prasugrel (neither depends on CYP2C19 for activation). The distractor is "increase the clopidogrel dose."
• Aspirin + asthma + nasal polyps = *Samter triad*/aspirin-exacerbated respiratory disease from leukotriene shunting; if antiplatelet therapy is mandatory, use a P2Y12 inhibitor or pursue aspirin desensitization.
• Suspected ACS: chewed, non–enteric-coated aspirin immediately, before ECG interpretation is finalized and regardless of prior aspirin dosing — the ACC/AHA acute coronary syndrome guidelines make this a universal first action. Nitroglycerin and morphine do not substitute.
• Atrial fibrillation plus PCI: do not leave the patient on indefinite "triple therapy." Contemporary ACC/AHA atrial fibrillation guidance favors a DOAC plus clopidogrel with early aspirin discontinuation to cut bleeding without a meaningful ischemic penalty.
• Clopidogrel + omeprazole/esomeprazole is a pharmacokinetic trap (CYP2C19 inhibition) — choose pantoprazole. Similarly, cilostazol is contraindicated in heart failure, and dipyridamole can cause coronary steal.